A rapid HPLC–MS/MS method for determining busulfan in hemolytic samples from children with hematopoietic stem cell transplantation. (30th June 2020)

• Record Type: Journal Article
• Authors: Jinjie, Yuan; Sun, Ning; Zhang, Shuyu; Feng, Xinying; Chen, Xijing; Zhao, Di; Zhao, Libo
• Is Part Of: Biomedical chromatography. Volume 34:Number 9(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-06-30
• Subjects: busulfan -- hemolytic samples -- HPLC–MS/MS -- HSCT -- TDM; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.4898
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: A rapid and sensitive method for the quantitative detection of busulfan (BU) in children's hemolytic samples by HPLC–tandem mass spectrometry (MS/MS) was established. In this study, the sample preparation procedure involved a one‐step protein precipitation with acetonitrile (ACN) solution, and the HPLC–MS/MS method used Hypersil GOLD C18 . The mobile phase consisted of 10 mM ammonium acetate solution (containing 0.1% formic acid) and ACN with a flow rate of 0.4 mL/min. Multiple reaction monitoring modes were used for quantitative analysis and the ion pairs of BU and BU‐d8 were m/z 263.9 → 150.9 and 272.0 → 159.0, respectively. BU had a good linearity in the range of 0.01–10 μg mL −1 . The intra‐ and inter‐day relative error was between –7.21% and 8.26%, and the coefficient of variation was less than 12.64%. The average extraction recovery rate in plasma samples was 99.76% ± 6.53%, and the matrix in normal plasma and hemolyzed plasma had no significant effect on the detection results. Normal and hemolytic samples could maintain good stability at 4, 25 and –40°C. As a result, this method is particularly suitable for determining BU in hemolytic samples from children with hematopoietic stem cell transplantation (HSCT), and this study provides the methodological basis for further research on the pharmacokinetics of BU in children with HSCT.